Physician profile
Christopher Barnard
NPI 1063505642
$3,957.22
in general payments reported to CMS, 2019-2025
29 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $123 · 2021: $1,256 · 2022: $66.79 · 2023: $23.19 · 2024: $1,079 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $1,125.00 | 2021 | |
| Abbvie INC. | $359.62 | 2024-2025 | |
| Amgen INC. | $323.19 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $283.56 | 2019-2025 | Adbry |
| Pfizer INC. | $276.49 | 2019-2025 | |
| Incyte Corporation | $234.94 | 2024-2025 | Opzelura |
| Genzyme Corporation | $196.65 | 2024-2025 | |
| Janssen Biotech, INC. | $125.31 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $125.26 | 2024-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $101.60 | 2024-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $101.16 | 2019-2021 | |
| Lilly USA, LLC | $88.50 | 2019-2024 | Zepbound, Taltz, Olumiant |
| Strata Skin Sciences, INC. | $73.50 | 2024-2025 | Xtrac |
| Organon LLC | $64.32 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $62.38 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.84 | 2019-2024 | |
| Galderma Laboratories, L.P. | $43.24 | 2025 | Nemluvio |
| Celgene Corporation | $42.05 | 2019 | |
| Sun Pharmaceutical Industries INC. | $38.70 | 2024 | |
| Merz North America, INC. | $38.24 | 2022 | |
| Ucb, INC. | $32.41 | 2024 | Bimzelx |
| Allergan, INC. | $31.57 | 2021 | |
| Mayne Pharma Commercial LLC | $24.25 | 2019 | |
| Organogenesis INC. | $22.15 | 2024 | |
| Apyx Medical Corporation | $21.54 | 2020 | |
| Cipher Pharmaceuticals US LLC | $20.44 | 2025 | Spinosad, Natroba |
| Solta Medical, A Division of Bausch Health US, LLC | $19.34 | 2025 | |
| Merck Sharp & Dohme LLC | $17.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.22 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Barnard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.